Evofem Biosciences Partners with Pharma 1 to Bring SOLOSEC to the Middle East Market

Reuters

2025/05/21

Evofem Biosciences Partners with Pharma 1 to Bring SOLOSEC to the Middle East Market

Evofem Biosciences Inc., a leader in women's health innovation, has entered into a partnership with Pharma 1 Drug Store LLC, a private Emirati healthcare company. The collaboration involves a License and Supply Agreement granting Pharma 1 exclusive rights to commercialize SOLOSEC® (secnidazole) in the Middle East. SOLOSEC is an FDA-approved, single-dose oral treatment for bacterial vaginosis and trichomoniasis, two prevalent sexual health conditions. Pharma 1 plans to submit for regulatory approval of SOLOSEC in the UAE by mid-2025. The agreement includes upfront and milestone-based payments to Evofem, and Pharma 1 will handle all regulatory, distribution, sales, marketing, and commercial functions in the region. This partnership aims to leverage Pharma 1's focus on sexual health to effectively launch SOLOSEC in the UAE and surrounding areas.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Evofem Biosciences Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: LA93046) on May 21, 2025, and is solely responsible for the information contained therein.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2537482933"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2537482933\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2537482933?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-05-21 20:59","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2537482933","market":"us","top_or_hot":-1,"title":"Evofem Biosciences Partners with Pharma 1 to Bring SOLOSEC to the Middle East Market","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Evofem Biosciences Partners with Pharma 1 to Bring SOLOSEC to the Middle East Market\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Evofem Biosciences Inc., a leader in women's health innovation, has entered into a partnership with Pharma 1 Drug Store LLC, a private Emirati healthcare company. The collaboration involves a License and Supply Agreement granting Pharma 1 exclusive rights to commercialize SOLOSEC® (secnidazole) in the Middle East. SOLOSEC is an FDA-approved, single-dose oral treatment for bacterial vaginosis and trichomoniasis, two prevalent sexual health conditions. Pharma 1 plans to submit for regulatory approval of SOLOSEC in the UAE by mid-2025. The agreement includes upfront and milestone-based payments to Evofem, and Pharma 1 will handle all regulatory, distribution, sales, marketing, and commercial functions in the region. This partnership aims to leverage Pharma 1's focus on sexual health to effectively launch SOLOSEC in the UAE and surrounding areas.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Evofem Biosciences Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: LA93046) on May 21, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Evofem Biosciences Partners with Pharma 1 to Bring SOLOSEC to the Middle East Market</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nEvofem Biosciences Partners with Pharma 1 to Bring SOLOSEC to the Middle East Market\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time smaller\">2025-05-21 20:59</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Evofem Biosciences Partners with Pharma 1 to Bring SOLOSEC to the Middle East Market\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Evofem Biosciences Inc., a leader in women's health innovation, has entered into a partnership with Pharma 1 Drug Store LLC, a private Emirati healthcare company. The collaboration involves a License and Supply Agreement granting Pharma 1 exclusive rights to commercialize SOLOSEC® (secnidazole) in the Middle East. SOLOSEC is an FDA-approved, single-dose oral treatment for bacterial vaginosis and trichomoniasis, two prevalent sexual health conditions. Pharma 1 plans to submit for regulatory approval of SOLOSEC in the UAE by mid-2025. The agreement includes upfront and milestone-based payments to Evofem, and Pharma 1 will handle all regulatory, distribution, sales, marketing, and commercial functions in the region. This partnership aims to leverage Pharma 1's focus on sexual health to effectively launch SOLOSEC in the UAE and surrounding areas.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Evofem Biosciences Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: LA93046) on May 21, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"EVFM","symbol_name":"Evofem Biosciences, Inc.","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250521:nNDL9xRfBk:1","article_id":"2537482933","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2537482933","pubTimestamp":1747832358,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Evofem Biosciences Inc., a leader in women's health innovation, has entered into a partnership with Pharma 1 Drug Store LLC, a private Emirati healthcare company. The collaboration involves a License and Supply Agreement granting Pharma 1 exclusive rights to commercialize SOLOSEC  in the Middle East. SOLOSEC is an FDA-approved, single-dose oral treatment for bacterial vaginosis and trichomoniasis, two prevalent sexual health conditions. Pharma 1 plans to submit for regulatory approval of SOLOSEC in the UAE by mid-2025. The agreement includes upfront and milestone-based payments to Evofem, and Pharma 1 will handle all regulatory, distribution, sales, marketing, and commercial functions in the region. This partnership aims to leverage Pharma 1's focus on sexual health to effectively launch SOLOSEC in the UAE and surrounding areas.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely info","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"EVFM":"Evofem Biosciences, Inc.","BK4007":"制药","BK4584":"避孕概念"},"translate_title":"Evofem Biosciences与Pharma 1合作将SOLOSEC引入中东市场","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"EVFM":0.9},"content_text":"Evofem Biosciences Partners with Pharma 1 to Bring SOLOSEC to the Middle East Market\n    \n\n        Evofem Biosciences Inc., a leader in women's health innovation, has entered into a partnership with Pharma 1 Drug Store LLC, a private Emirati healthcare company. The collaboration involves a License and Supply Agreement granting Pharma 1 exclusive rights to commercialize SOLOSEC® (secnidazole) in the Middle East. SOLOSEC is an FDA-approved, single-dose oral treatment for bacterial vaginosis and trichomoniasis, two prevalent sexual health conditions. Pharma 1 plans to submit for regulatory approval of SOLOSEC in the UAE by mid-2025. The agreement includes upfront and milestone-based payments to Evofem, and Pharma 1 will handle all regulatory, distribution, sales, marketing, and commercial functions in the region. This partnership aims to leverage Pharma 1's focus on sexual health to effectively launch SOLOSEC in the UAE and surrounding areas.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Evofem Biosciences Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: LA93046) on May 21, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}